Home Biotechnology UCB S.A.
U

UCB S.A.

Profile managed by Bizz Id
Belgium 500+ employees 1928

Description

Biopharmaceutical company founded in 1928 and headquartered in Brussels, Belgium. It focuses on severe neurological and autoimmune diseases, with medicines in epilepsy, Parkinson's disease, myasthenia gravis, inflammatory diseases and osteoporosis. It has more than 10,000 employees.

Products

8 products
Bepranemab

Anti-tau monoclonal antibody. Alzheimer's disease, Phase 2 (to start H1 2027).

Under development

Finished product (FDF)

Verified on 2026-10-21

Bepranemab: see suppliers →

Bimekizumab

Brand: Bimzelx. Monoclonal antibody against IL-17A and IL-17F. Plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa. In development for new indications (paediatric HS and psoriasis, palmoplantar pustulosis, juvenile idiopathic arthritis).

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Bimekizumab: see suppliers →

Certolizumab pegol

Brand: Cimzia. Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis (incl. non-radiographic), Crohn's disease, plaque psoriasis, polyarticular juvenile idiopathic arthritis.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Certolizumab pegol: see suppliers →

Cizutamig

BCMA x CD3 bispecific T-cell engager. Myasthenia gravis and SARD-associated interstitial lung disease, Phase 2 (planned to start end 2026).

Under development

Finished product (FDF)

Verified on 2026-10-21

Cizutamig: see suppliers →

Dapirolizumab pegol

Pegylated anti-CD40L Fab fragment, co-developed with Biogen. Systemic lupus erythematosus, Phase 3 (second Phase 3 study).

Under development

Finished product (FDF)

Verified on 2026-10-21

Dapirolizumab pegol: see suppliers →

Galvokimig

Multi-specific antibody against IL-13, IL-17A and IL-17F. Atopic dermatitis Phase 2b; non-cystic fibrosis bronchiectasis and COPD Phase 2.

Under development

Finished product (FDF)

Verified on 2026-10-21

Galvokimig: see suppliers →

Romosozumab

Brand: Evenity. Osteoporosis.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Romosozumab: see suppliers →

Rozanolixizumab

Brand: Rystiggo (rozanolixizumab-noli). FcRn-inhibiting monoclonal antibody. Myasthenia gravis. In development: MOG antibody disease and ocular myasthenia gravis (Phase 3).

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Rozanolixizumab: see suppliers →

Contact company

Register for free to see this company’s contact details and get in touch.

Register - Free